Atara Q1 2022 Earnings Report
Key Takeaways
Atara Biotherapeutics reported a net loss of $88.1 million, or $0.87 per share, for the first quarter of 2022. As of March 31, 2022, cash, cash equivalents, and short-term investments totaled $301.8 million, excluding the $100 million upfront payment from FUJIFILM Diosynth Biotechnologies (FDB) received in April.
Anticipated European Commission approval for Tab-cel remains on track for Q4 2022, with ongoing dialogue with the FDA.
Cash, cash equivalents and short-term investments totaled $301.8 million as of March 31, 2022.
FDA Fast-Track Designated ATA188 interim analysis on-track for June 2022.
Cash is expected to fund planned operations into Q4 2023, following the sale of the cell therapy manufacturing facility to FUJIFILM for $100 million.
Atara
Atara
Forward Guidance
Atara believes that its cash as of March 31, 2022, together with the $100.0 million received from FDB on April 4, 2022, will be sufficient to fund the Company’s planned operations into the fourth quarter of 2023